Myelodysplastic Syndrome (MDS) Progression: Outcomes of Failed Treatment

Myelodysplastic Syndromes (MDS) are clonal hematopoietic stem cell disorders with ineffective hematopoiesis and risk of transformation to acute myeloid leukemia (AML).

Consequences of Treatment Failure / Disease Progression

1. Bone Marrow Failure

  • Worsening cytopenias: anemia (transfusion dependence), thrombocytopenia (bleeding), neutropenia (infections).
  • Quality of life decline; transfusion iron overload (cardiac, endocrine, hepatic).

2. Leukemic Transformation

  • Progression to AML (≥20% blasts in marrow/blood).
  • Higher-risk IPSS-R categories (Intermediate, High, Very High) have 25–50% 3-year AML risk.
  • AML from MDS has worse prognosis than de novo AML (complex karyotype, TP53 mutations, resistance).

3. Other Complications

  • Splenomegaly, hepatomegaly, lymphadenopathy (extramedullary hematopoiesis).
  • Autoimmune phenomena (vasculitis, pure red cell aplasia).
  • Infection-related mortality (leading cause of death in lower-risk MDS).

Prognostic Stratification

  • IPSS-R (Revised International Prognostic Scoring System): Cytogenetics, blast %, cytopenias → 5 risk groups (Very Low to Very High); median survival 0.8–8.8 years.
  • Molecular IPSS (IPSS-M): Incorporates mutation profile (TP53, FLT3, RAS, splicing factors) – more precise.

Therapeutic Options at Progression

  • Higher-intensity hypomethylating agents (azacitidine, decitabine) – may delay AML.
  • Clinical trials (novel agents: splicing modulators, IDH inhibitors, immune therapies).
  • Allogeneic HCT – only curative; age/comorbidity/fitness dependent; best in higher-risk before AML transformation.
  • Supportive care: transfusions, growth factors (EPO, G-CSF), iron chelation, infection prophylaxis, palliative care integration.

Multidisciplinary MDS center care optimizes sequencing and quality of life.

Blood Disorders - Related Articles